| HIV Infections

Biktarvy vs Pifeltro

Side-by-side clinical, coverage, and cost comparison for hiv infections.

Deep comparison between: Biktarvy vs Pifeltro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsPifeltro has a higher rate of injection site reactions vs Biktarvy based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Pifeltro but not Biktarvy, including UnitedHealthcare

Category

Biktarvy

Pifeltro

At A Glance

RouteOral

FrequencyDaily

ClassINSTI + NRTI combination

RouteOral

FrequencyOnce daily

ClassNNRTI

Indications

HIV Infections

HIV Infections

Dosing

HIV Infections - adults and pediatric >= 25 kg One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; on hemodialysis days, administer after hemodialysis completion.

HIV Infections - pediatric 14 kg to < 25 kg One tablet (30 mg BIC/120 mg FTC/15 mg TAF) taken orally once daily with or without food.

HIV Infections - virologically-suppressed pregnant individuals One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; monitor viral load closely due to lower drug exposures during pregnancy.

HIV Infections One 100 mg tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.

HIV Infections (with rifabutin) One 100 mg tablet orally twice daily (approximately 12 hours apart) for the duration of rifabutin co-administration.

Contraindications

Co-administration with dofetilide due to potential for increased dofetilide plasma concentrations and serious or life-threatening events
Co-administration with rifampin due to substantially decreased BIC plasma concentrations, which may result in loss of therapeutic effect and development of resistance

Co-administration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin (anticonvulsants)
Co-administration with enzalutamide (androgen receptor inhibitor)
Co-administration with rifampin or rifapentine (antimycobacterials)
Co-administration with mitotane (cytotoxic agent)
Co-administration with St. John's wort (Hypericum perforatum)

Drug Interactions

1911View drug interactions

935View drug interactions

Adverse Reactions

Most common (>=5%) Diarrhea, nausea, headache

Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis

Postmarketing Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, angioedema, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria, weight increased

Most common (>=5%) Nausea, headache, fatigue, diarrhea, abdominal pain

Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, hepatic enzyme increased

Pharmacology

BIKTARVY is a fixed-dose combination antiretroviral containing bictegravir (BIC), an integrase strand transfer inhibitor (INSTI) that blocks integration of HIV-1 DNA into host genomic DNA, plus emtricitabine (FTC) and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs) that terminate viral DNA chain elongation by competing with natural nucleoside substrates.

Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 that inhibits viral replication by non-competitive inhibition of HIV-1 reverse transcriptase and does not inhibit human cellular DNA polymerases alpha, beta, or mitochondrial DNA polymerase gamma.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Biktarvy